Volume 69 Received 18 February 2013 | ||||||||||
| ||||||||||
aLaboratoire de Chimie Organique Appliquée, Université Sidi Mohamed Ben Abdallah, Faculté des Sciences et Techniques, Route d'immouzzer, BP 2202 Fès, Morocco,bLaboratoire de Chimie Organique Hétérocyclique URAC21, Faculté des Sciences, Université Mohammed V-Agdal, Avenue Ibn Battouta, BP 1014, Rabat, Morocco,cINANOTECH (Institute of Nanomaterials and Nanotechnology), MAScIR, Av. de l'Armée Royale, Rabat, Morocco, and dLaboratoire de Chimie du Solide Appliquée, Faculté des Sciences, Université Mohammed V-Agdal, Avenue Ibn Battouta, BP 1014, Rabat, Morocco
Correspondence e-mail: ouzidan@yahoo.fr
The benzimidazolone residue in the title molecule, C10H9N3O3, is almost planar, with the largest deviation from the mean plane being 0.016 (2) Å for the C atom linked to the nitro group. This plane is nearly perpendicular to the 1-allyl chain as indicated by the C-N-C-C torsion angle of 90.9 (3)°. The fused-ring system makes a dihedral angle of 5.6 (3)° with the nitro group, leading to a synperiplanar conformation. In the crystal, zigzag supramolecular chains are formed along the a axis by N-H
O hydrogen bonds.
For pharmacological and biochemical properties of benzimidazoles and derivatives, see: Al Muhaimeed (1997
); Scott et al. (2002
); Nakano et al. (2000
); Zhu et al. (2000
); Zarrinmayeh et al. (1998
). For related structures, see: Ouzidan et al. (2011a
,b
).
|
|
|
| |||||||||||||||||
Data collection: APEX2 (Bruker, 2009
); cell refinement: SAINT (Bruker, 2009
); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008
); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008
); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012
); software used to prepare material for publication: PLATON (Spek, 2009
) and publCIF (Westrip, 2010
).
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: TK5200 ).
The authors thank the Unit of Support for Technical and Scientific Research (UATRS, CNRST) for the X-ray data measurements.
Al Muhaimeed, H. (1997). J. Int. Med. Res. 25, 175-181.
![[PubMed]](../../../../../../logos/pubmedborder.gif)
Bruker (2009). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849-854.
![[details]](../../../../../../j/graphics/details.gif)
Nakano, H., Inoue, T., Kawasaki, N., Miyataka, H., Matsumoto, H., Taguchi, T., Inagaki, N., Nagai, H. & Satoh, T. (2000). Bioorg. Med. Chem. 8, 373-380.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Ouzidan, Y., Kandri Rodi, Y., Butcher, R. J., Essassi, E. M. & El Ammari, L. (2011a). Acta Cryst. E67, o283.
![[details]](../../../../../../e/graphics/details.gif)
Ouzidan, Y., Kandri Rodi, Y., Saffon, N., Essassi, E. M. & Ng, S. W. (2011b). Acta Cryst. E67, o520.
![[details]](../../../../../../e/graphics/details.gif)
Scott, L. J., Dunn, C. J., Mallarkey, G. & Sharpe, M. (2002). Drugs, 62, 1503-1538.
![[ChemPort]](../../../../../../logos/chemportborder.gif)
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
![[details]](../../../../../../a/graphics/details.gif)
Spek, A. L. (2009). Acta Cryst. D65, 148-155.
![[details]](../../../../../../d/graphics/details.gif)
Westrip, S. P. (2010). J. Appl. Cryst. 43, 920-925.
![[details]](../../../../../../j/graphics/details.gif)
Zarrinmayeh, H., Nunes, A. M., Ornstein, P. L., Zimmerman, D. M., Arnold, M. B., Schober, D. A., Gackenheimer, S. L., Bruns, R. F., Hipskind, P. A., Britton, T. C., Cantrell, B. E. & Gehlert, D. R. (1998). J. Med. Chem. 41, 2709-2719.
![[PubMed]](../../../../../../logos/pubmedborder.gif)
Zhu, Z., Lippa, B., Drach, J. C. & Townsend, L. B. (2000). J. Med. Chem. 43, 2430-2437.
![[ChemPort]](../../../../../../logos/chemportborder.gif)